Visiongain publishes Cardiac Rhythm Management Devices Market Report 2020-2030

18 June 2020
Pharma

Visiongain has launched a new pharma report Cardiac Rhythm Management Devices Market Report 2020-2030: Forecasts by Product (Pacemakers (Implantable & External), Cardiac Resynchronization Therapy (CRT-Defibrillator & CRT-Pacemakers), Defibrillators (Implantable Cardioverter Defibrillators (ICD) & External Defibrillator)), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).

The global Cardiac Rhythm Management (CRM) Devices Market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that the market is projected to witness a healthy growth rate owing to the technological advancements coupled with the high adoption rate of cardiac rhythm management devices across the developed economies.

To access the data contained in this document please email contactus@visiongain.com

Over recent years, heart irregularities have been the primary cause of death. According to estimates by the World Health Organization (WHO), around 17.9 million mortality occurs each year in cardiovascular diseases (CVDs). Because CVDs are slow to develop symptoms, it is usually known as the "silent epidemic." They are also considered to be one of the most costly conditions for treatment. CRM devices are not only used for the management and monitoring of heart problems but are also used for healing, repair, and healing. In America and Europe, the increase in aging populations is likely to cause an increase in the number of patients with heart rhythm disorders.

However, the therapeutic radiation used for cancer can influence an implantable patient's operation. Implantable equipment technology uses a CMOS, which is vulnerable to damage by therapeutic doses of radiation but can vary by type of equipment used. The fact that implants are highly susceptible and their malfunction can have serious consequences is one of the main factors limiting the extent to which cardiac rhythm management devices can be used. On the other hand, the high cost of these devices restricts the market growth.

North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing presence of CVDs patient pool in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the Cardiac Rhythm Management Devices Market growth over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global cardiac rhythm management devices market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Cardiac Rhythm Management Devices Market.

The comprehensive market report features companies such as Abbott Laboratories, Asahi Kasei Corporation, AliveCor, BioTelemetry, Boston Scientific, Biotronik, BPL Medical Technologies, CardioComm Solutions, EPI Mobile Health Solutions, GE Healthcare, Hill-Rom Holdings, Koninklijke Philips, Lepu Medical Technology, Medtronic, Nihon Kohden, Shenzhen Mindray Bio-Medical Electronics, among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever